Medicare Part D is really the model going forward, says David Ricks, Eli Lilly CEO, talking about his meeting with President Trump and the pharma industry's move to provide competitive pricing on prescriptions. Also Ricks shares his thoughts on tax reform and the impact of regulations.
Jim Cramer identified a concerns lurking beneath the surface among shareholders and executives in the business community.
Jim Cramer expected Donald Trump to walk into his meeting with pharma executives with a baseball bat. Instead, he jawboned them.
CNBC's Meg Tirrell reports on President Trump's meeting with big pharmaceutical CEOs, and how it is impacting the biotech sector. The "Fast Money" traders weigh in.
Tony Coles, Yumanity Therapeutics CEO, former Onyx CEO, weighs in on President Trump's drug pricing rhetoric and meeting with pharma leaders. With CNBC's Meg Tirrell.
Ronald Klain, former White House senior advisor, and Vamil Divan, Credit Suisse pharma analyst, weigh in on President Trump's plans to bring down drug prices and the potential impact on the pharmaceutical industry. With CNBC's Meg Tirrell.